Differential Reprogramming of Isogenic Colorectal Cancer Cells by Distinct Activating KRAS Mutations

Oncogenic mutations of Ras at codons 12, 13, or 61, that render the protein constitutively active, are found in ∼16% of all cancer cases. Among the three major Ras isoforms, KRAS is the most frequently mutated isoform in cancer. Each Ras isoform and tumor type displays a distinct pattern of codon-specific mutations. In colon cancer, KRAS is typically mutated at codon 12, but a significant fraction of patients have mutations at codon 13. Clinical data suggest different outcomes and responsiveness to treatment between these two groups. To investigate the differential effects upon cell status associated with KRAS mutations we performed a quantitative analysis of the proteome and phosphoproteome of isogenic SW48 colon cancer cell lines in which one allele of the endogenous gene has been edited to harbor specific KRAS mutations (G12V, G12D, or G13D). Each mutation generates a distinct signature, with the most variability seen between G13D and the codon 12 KRAS mutants. One notable example of specific up-regulation in KRAS codon 12 mutant SW48 cells is provided by the short form of the colon cancer stem cell marker doublecortin-like Kinase 1 (DCLK1) that can be reversed by suppression of KRAS.

[1]  I. Prior,et al.  Quantitative proteomic analysis of compartmentalized signaling networks. , 2014, Methods in enzymology.

[2]  M. G. Koerkamp,et al.  Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer , 2013, British Journal of Cancer.

[3]  E. Gerner,et al.  Caveolin‐1 is a novel regulator of K‐RAS‐dependent migration in colon carcinogenesis , 2013, International journal of cancer.

[4]  Robert G. Parton,et al.  Caveolae as plasma membrane sensors, protectors and organizers , 2013, Nature Reviews Molecular Cell Biology.

[5]  R. Kageyama,et al.  Dclk1 distinguishes between tumor and normal stem cells in the intestine , 2012, Nature Genetics.

[6]  Li Li,et al.  Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines* , 2012, The Journal of Biological Chemistry.

[7]  C. Bokemeyer,et al.  Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Prior,et al.  Global snapshot of the influence of endocytosis upon EGF receptor signaling output. , 2012, Journal of proteome research.

[9]  J. Lamb,et al.  A Comprehensive Characterization of Genome-Wide Copy Number Aberrations in Colorectal Cancer Reveals Novel Oncogenes and Patterns of Alterations , 2012, PloS one.

[10]  I. Gelman,et al.  Pivotal Role of AKAP12 in the Regulation of Cellular Adhesion Dynamics: Control of Cytoskeletal Architecture, Cell Migration, and Mitogenic Signaling , 2012, Journal of signal transduction.

[11]  A. Tamura,et al.  Crystal structures of the state 1 conformations of the GTP‐bound H‐Ras protein and its oncogenic G12V and Q61L mutants , 2012, FEBS letters.

[12]  Julian Downward,et al.  Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies , 2012, Cell Research.

[13]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[14]  C. Bellows,et al.  DCLK1 immunoreactivity in colorectal neoplasia , 2012, Clinical and experimental gastroenterology.

[15]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[16]  Min Yu,et al.  TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers , 2012, Cell.

[17]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[18]  Y. Yoshikawa,et al.  Solution Structure of the State 1 Conformer of GTP-bound H-Ras Protein and Distinct Dynamic Properties between the State 1 and State 2 Conformers* , 2011, The Journal of Biological Chemistry.

[19]  M. Guan,et al.  Re-Expression of AKAP12 Inhibits Progression and Metastasis Potential of Colorectal Carcinoma In Vivo and In Vitro , 2011, PloS one.

[20]  W. Hsu,et al.  Phosphoproteomics Identifies Oncogenic Ras Signaling Targets and Their Involvement in Lung Adenocarcinomas , 2011, PloS one.

[21]  Kristoffer T G Rigbolt,et al.  GProX, a User-Friendly Platform for Bioinformatics Analysis and Visualization of Quantitative Proteomics Data* , 2011, Molecular & Cellular Proteomics.

[22]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[23]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[24]  Hans Robert Kalbitzer,et al.  Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis* , 2010, The Journal of Biological Chemistry.

[25]  B. Su,et al.  SSeCKS/Gravin/AKAP12 Inhibits Cancer Cell Invasiveness and Chemotaxis by Suppressing a Protein Kinase C- Raf/MEK/ERK Pathway* , 2009, The Journal of Biological Chemistry.

[26]  I. Deary,et al.  Variants in Doublecortin- and Calmodulin Kinase Like 1, a Gene Up-Regulated by BDNF, Are Associated with Memory and General Cognitive Abilities , 2009, PloS one.

[27]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[28]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[29]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[30]  M. Mann,et al.  Universal sample preparation method for proteome analysis , 2009, Nature Methods.

[31]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[32]  J. Settleman,et al.  Isoform-specific ras functions in development and cancer. , 2009, Future oncology.

[33]  B. Maček,et al.  High accuracy mass spectrometry in large-scale analysis of protein phosphorylation. , 2009, Methods in molecular biology.

[34]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[35]  Akhilesh Pandey,et al.  Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS , 2008, Proceedings of the National Academy of Sciences.

[36]  S. Wiseman,et al.  Caveolin-1 in tumor progression: the good, the bad and the ugly , 2008, Cancer and Metastasis Reviews.

[37]  Tony Pawson,et al.  NetworKIN: a resource for exploring cellular phosphorylation networks , 2007, Nucleic Acids Res..

[38]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[39]  S. Fesik,et al.  Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells , 2007, Molecular Cancer Therapeutics.

[40]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[41]  J. Minna,et al.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.

[42]  S. Gygi,et al.  An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets , 2005, Nature Biotechnology.

[43]  J. Mesirov,et al.  An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis , 2005, Nature Genetics.

[44]  A. Rosenthal,et al.  Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells , 2004, Oncogene.

[45]  T. Waldman,et al.  B-Raf Is Dispensable for K-Ras-Mediated Oncogenesis in Human Cancer Cells 1 , 2004, Cancer Research.

[46]  R. Labianca,et al.  Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  O. Reiner,et al.  Cleavage of Doublecortin-like Kinase by Calpain Releases an Active Kinase Fragment from a Microtubule Anchorage Domain* , 2001, The Journal of Biological Chemistry.

[48]  K. Furge,et al.  Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Capellá,et al.  K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. , 2000, Cancer research.

[50]  Johannes Zuber,et al.  A genome-wide survey of RAS transformation targets , 2000, Nature Genetics.

[51]  S. Mcconnell,et al.  Doublecortin Is a Developmentally Regulated, Microtubule-Associated Protein Expressed in Migrating and Differentiating Neurons , 1999, Neuron.

[52]  M. Fiscella,et al.  Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis , 1998, Oncogene.

[53]  T. A. Link,et al.  Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. , 1998, Science.

[54]  J. Engelman,et al.  Caveolin‐mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo , 1998, FEBS letters.

[55]  S. Finkelstein,et al.  Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K‐ras‐2 mutation type , 1993, Cancer.

[56]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[57]  R. Goody,et al.  Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. , 1988, The Journal of biological chemistry.

[58]  F. McCormick,et al.  Biochemical and biological properties of the human N-ras p21 protein , 1987, Molecular and cellular biology.

[59]  P. Seeburg,et al.  Biological properties of human c-Ha-ras1 genes mutated at codon 12 , 1984, Nature.